Positive Phase III Diabetes Data with Lixisenatide Announced by Zealand Pharma's Partner sanofi-aventis
The key highlights of the announcement are:
- Phase III study endpoints with Lixisenatide in diabetes successfully met in first reported study
- Improved glycemic control in T2DM patients dosed once daily as monotherapy
- Lixisenatide was generally well tolerated with no significant adverse events
- Complete study findings submitted for presentation at EASD in September 2010
- Phase III program with the combination of Lixisenatide/Lantus® expected to commence in 2010 - Lantus® is the number-one sold insulin in the world in both sales and units (source: IMS, 2009 sales)
Commenting on the announcement David Solomon, Chief Executive Officer and President of Zealand Pharma, said: "We are delighted to note today's announcement from our strong partner, sanofi-aventis, regarding the first successful Phase III results from the GetGoal study for Lixisenatide. These results represent a significant achievement for Zealand Pharma, and for patients with T2DM. We look forward to the ongoing clinical development of Lixisenatide by sanofi-aventis and are extremely excited about the future initiation of new Phase III studies of Lixisenatide in combination with Lantus® which are expected to commence later this year."
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.